BFC
IONS icon

Bedel Financial Consulting’s Ionis Pharmaceuticals IONS Stock Holding History

Bedel Financial Consulting’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-38
Closed -$1K – 1016
2021
Q4 		$1K Hold
38
– – ﹤0.01% 951
2021
Q3 		$1K Hold
38
– – ﹤0.01% 938
2021
Q2 		$2K Hold
38
– – ﹤0.01% 886
2021
Q1 		$2K Hold
38
– – ﹤0.01% 853
2020
Q4 		$2K Hold
38
– – ﹤0.01% 753
2020
Q3 		$2K Hold
38
– – ﹤0.01% 715
2020
Q2 		$2K Sell
38
-100
-72% -$5.56K ﹤0.01% 689
2020
Q1 		$7K Buy
138
+100
+263% +$5.57K ﹤0.01% 528
2019
Q4 		$2K Hold
38
– – ﹤0.01% 682
2019
Q3 		$2K Buy
+38
New +$2.48K ﹤0.01% 655

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Bedel Financial Consulting's IONS Position: Q1 2022 in Review

Bedel Financial Consulting sold out of Ionis Pharmaceuticals (IONS) in Q1 2022, closing a stake of 38 shares — an estimated $1K sold.

Bedel Financial Consulting first reported a position in IONS in Q3 2019 and held it in 10 quarters. The position peaked at $7K in Q1 2020. 332 funds tracked by Wall St. Rank hold IONS as of Q1 2022.

  • Bedel Financial Consulting reported no remaining Ionis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 38 Ionis Pharmaceuticals shares in Q1 2022, an estimated $1K.
  • Bedel Financial Consulting first reported a position in Ionis Pharmaceuticals in Q3 2019 and held it in 10 quarters.
  • Bedel Financial Consulting's Ionis Pharmaceuticals position peaked at $7K in Q1 2020.
  • 332 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2022.

Based on Bedel Financial Consulting's 13F filing for Q1 2022, filed 19 Apr 2022.